Safety and Efficacy of Rituximab Plus Bendamustine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients

被引：1

作者：

Arcari, Annalisa ^{[1
]}

Chiappella, Annalisa ^{[2
]}

Valenti, Vanessa ^{[1
]}

Zanlari, Luca ^{[3
]}

Tani, Monica ^{[4
]}

Marasca, Roberto ^{[5
]}

Cabras, Maria Giuseppina ^{[6
]}

Spina, Michele ^{[7
]}

Santagostino, Alberto ^{[8
]}

Ilariucci, Fiorella ^{[9
]}

Carli, Giuseppe ^{[10
]}

Musto, Pellegrino ^{[11
]}

Savini, Paolo ^{[12
]}

Marino, Dario ^{[13
]}

Ghio, Francesco ^{[14
]}

Gentile, Massimo ^{[15
]}

Cox, Maria Christina ^{[16
]}

Della Seta, Roberta ^{[17
]}

Vallisa, Daniele ^{[1
]}

机构：

[1] Osped Civile G Da Saliceto, Piacenza, Italy

[2] SC Ematol Azienda Osped Citta Salute & Sci, Turin, Italy

[3] Osped Fiorenzuola dArda, Day Hosp Med Interna, Piacenza, Italy

[4] Osped Santa Maria Croci, Ravenna, Italy

[5] Univ Modena & Reggio Emilia, Modena, Italy

[6] ASL Cagliari, Cagliari, Italy

[7] Ctr Riferimento Oncol, I-33081 Aviano, Italy

[8] Osped S Andrea Vercelli, Vercelli, Italy

[9] Arcispedale S Maria Nuova IRCCS, Reggio Emilia, Italy

[10] Univ Verona, I-37100 Verona, Italy

[11] IRCCS Ctr Riferimento Oncol Basilicata, Rionero In Vulture, Italy

[12] Osped Infermi, Faenza, Italy

[13] Ist Oncol Veneto IRCCS, Padua, Italy

[14] Univ Pisa, Pisa, Italy

[15] Osped Annunziata, Cosenza, Italy

[16] Azienda Osped S Andrea, Rome, Italy

[17] AUSL1, Carrara, Italy

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

10.1182/blood.V124.21.3074.3074

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
Kayoko Murayama
Toru Kiguchi
Koji Izutsu
Yoshihiro Kameoka
Michihiro Hidaka
Harumi Kato
Shinya Rai
Junya Kuroda
Kenichi Ishizawa
Satoshi Ichikawa
Kiyoshi Ando
Michinori Ogura
Koji Fukushima
Yasuhito Terui
[J]. Annals of Hematology, 2022, 101 : 979 - 989
[2] Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
Murayama, Kayoko
Kiguchi, Toru
Izutsu, Koji
Kameoka, Yoshihiro
Hidaka, Michihiro
Kato, Harumi
Rai, Shinya
Kuroda, Junya
Ishizawa, Kenichi
Ichikawa, Satoshi
Ando, Kiyoshi
Ogura, Michinori
Fukushima, Koji
Terui, Yasuhito
[J]. ANNALS OF HEMATOLOGY, 2022, 101 (05) : 979 - 989
[3] Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study
Arcari, Annalisa
Chiappella, Annalisa
Spina, Michele
Zanlari, Luca
Bernuzzi, Patrizia
Valenti, Vanessa
Tani, Monica
Marasca, Roberto
Cabras, Maria Giuseppina
Zambello, Renato
Santagostino, Alberto
Ilariucci, Fiorella
Carli, Giuseppe
Musto, Pellegrino
Savini, Paolo
Marino, Dario
Ghio, Francesco
Gentile, Massimo
Cox, Maria Christina
Vallisa, Daniele
[J]. LEUKEMIA & LYMPHOMA, 2016, 57 (08) : 1823 - 1830
[4] Bendamustine/rituximab in relapsed or refractory diffuse large B-cell lymphoma
Vacirca, J. L.
Acs, P. I.
Shimkus, B. J.
Rosen, P. J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[5] Bendamustine plus Rituximab as Treatment for Elderly Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Vacirca, Jeffrey
Tabbara, Imad
Acs, Peter
Shumaker, Grace
[J]. BLOOD, 2010, 116 (21) : 1157 - 1157
[6] Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Ohmachi, Ken
Niitsu, Nozomi
Uchida, Toshiki
Kim, Seok Jin
Ando, Kiyoshi
Takahashi, Naoki
Takahashi, Naoto
Uike, Naokuni
Eom, Hyeon Seok
Chae, Yee Soo
Terauchi, Takashi
Tateishi, Ukihide
Tatsumi, Mitsuaki
Kim, Won Seog
Tobinai, Kensei
Suh, Cheolwon
Ogura, Michinori
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (17) : 2103 - +
[7] Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world
Vodicka, Prokop
Benesova, Katerina
Janikova, Andrea
Prochazka, Vit
Belada, David
Mocikova, Heidi
Steinerova, Katerina
Duras, Juraj
Karban, Josef
Hanackova, Veronika
Sykorova, Alice
Obr, Ales
Trneny, Marek
[J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (02) : 162 - 165
[8] Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma
Ivanov, Vadim
Coso, Diane
Chetaille, Bruno
Esterni, Benjamin
Olive, Daniel
Aurran-Schleinitz, Therese
Schiano, Jean Marc
Stoppa, Anne-Marie
Broussais-Guillaumot, Florence
Blaise, Didier
Bouabdallah, Reda
[J]. LEUKEMIA & LYMPHOMA, 2014, 55 (11) : 2508 - 2513
[9] Phase III trial of bendamustine plus rituximab for relapsed or refractory diffuse large B-cell lymphoma in Japan
Kiguchi, Toru
Terui, Yasuhito
Izutsu, Koji
Kameoka, Yoshihiro
Hidaka, Michihiro
Kato, Harumi
Matsumura, Itaru
Kuroda, Junya
Ishizawa, Kenichi
Ichikawa, Satoshi
Ando, Kiyoshi
Ogura, Michinori
Tobinai, Kensei
Fukushima, Koji
Murayama, Kayoko
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S304 - S304
[10] BENDAMUSTINE PLUS RITUXIMAB FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: A RETROSPECTIVE STUDY
Merchionne, F.
Quintana, G.
Minoia, C.
Guarini, A.
Galise, I.
Quarta, G.
Loseto, G.
Melpignano, A.
[J]. HAEMATOLOGICA, 2014, 99 : 696 - 697

← 1 2 3 4 5 →